Last reviewed · How we verify
FOSFOMYCIN TROMETHAMINE
FOSFOMYCIN TROMETHAMINE is a drug. It is currently FDA-approved (first approved 1996).
At a glance
| Generic name | FOSFOMYCIN TROMETHAMINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
- Diarrhea
- Vaginitis
- Nausea
- Headache
- Dizziness
- Asthenia
- Dyspepsia
- Rhinitis
- Back pain
- Dysmenorrhea
- Pharyngitis
- Abdominal pain
Serious adverse events
- Anaphylaxis
- Aplastic anemia
- Angioedema
- Toxic megacolon
- Hepatic necrosis
- Cholestatic jaundice
- Asthma exacerbation
- Optic neuritis
- Hearing loss
Key clinical trials
- FOsfomycin for Male Urinary Tract Infection (PHASE3)
- Therapeutic Options for CRAB (PHASE4)
- Preoperative Prophylactic Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Postpercutaneous Nephrolithotomy Infectious Complications and Sepsis. (NA)
- Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder (PHASE4)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- NextGen - Clinical Implication of Next Generation Sequencing (PHASE4)
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOSFOMYCIN TROMETHAMINE CI brief — competitive landscape report
- FOSFOMYCIN TROMETHAMINE updates RSS · CI watch RSS
Frequently asked questions about FOSFOMYCIN TROMETHAMINE
What is FOSFOMYCIN TROMETHAMINE?
FOSFOMYCIN TROMETHAMINE is a Small molecule drug.
When was FOSFOMYCIN TROMETHAMINE approved?
FOSFOMYCIN TROMETHAMINE was first approved on 1996.
What development phase is FOSFOMYCIN TROMETHAMINE in?
FOSFOMYCIN TROMETHAMINE is FDA-approved (marketed).
What are the side effects of FOSFOMYCIN TROMETHAMINE?
Common side effects of FOSFOMYCIN TROMETHAMINE include Diarrhea, Vaginitis, Nausea, Headache, Dizziness, Asthenia. Serious adverse events: Anaphylaxis, Aplastic anemia, Angioedema, Toxic megacolon.
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing